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Tumor Necrosis Factor Activity Increases in the Early 
Response to Trauma 
KelXin L. Ferguson, MD, Paul Tuheri, MD, Jorge Rodriguez, MD, Vijay Tonapi, BS, 
Anthony Curdellio, BS, Ron Dechert, RRT 
I ABSTRACT 
Objectives: 1) To determine whether tumor necrosis factor (TNF) up-regulation occurs in the first hours 
following severe injury. 2) To determine whether the time from injury to blood sampling affects the probability 
of detecting TNF. 
Methods: A prospective, cross-sectional study was performed using a convenience sample of adult major 
trauma patients (“patients”) treated at a university hospital ED (Level-1 trauma center) and 20 healthy vol- 
unteers (“controls”). The time interval from injury to specimen collection (AT), the injury severity scale 
(ISS) score, patient demographics, and quantitative cytokine [TNF and interleukin (IL-6, IL-8)] levels were 
measured. In the patients, cytokine levels were analyzed as a function of AT (using first hourly cutoff points 
and then the median T as an arbitrary cutoff point) with and without potential confounders (e.g., ISS, age, 
gender). 
Results: The mean AT was 92.8 2 49.2 min (range 10-210 min, median 82 min). In the controls, TNF 
activity was present in 96%, with a mean level of 125 pg/mL. The controls showed no baseline IL-6 activity 
and only 10% had a measurable baseline IL-8 level. In the patients, TNF was present in 93%, with a mean 
level of 628 -t 138 pg/mL. When the patients’ specimens were divided at the median to obtain roughly equal- 
sized groups, more TNF levels were elevated >2.5 SD above the controls in t h e  early vs late group ( 5  1 % vs 
30%; p = 0.07). The mean levels of TNF and IL-8 also were higher in the early vs late group (756 vs 530 
and 287 vs 135, respectively; p < 0.05). 
Conclusions: TNF levels are elevated in the immediate 4 hours post-injury. Previous investigators’ inability 
to detect TNF activity increases may be related to delays in sampling. These results are consistent with the 
theory that increased TNF activity occurs early after major trauma and may initiate subsequent cytokine 
activity. 
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I ‘The systemic inflammatory response has been impli- 
cated in posttraumatic adult respiratory distress syndrome 
(ARDS) and multiple organ dysfunction syndrome 
(MODS).’ Injection of tumor necrosis factor (TNF) in- 
duces subsequent increases i n  other inflammatory cyto- 
kines and reproduces the pathophysiologic and clinical 
picture of sepsis and its attendant complications including 
MODS.’ ’ Previous investigators of the posttraumatic in- 
flammatory response have not detected increases in TNF, 
despite the presence of “downstream” cytokines such as 
interleukin (ILj-6, IL-8, and However, many of 
these studies collected specimens many hours after injury. 
Since the half-life of TNF is approximately 90 minutes, 
we hypothesize that the absence of TNF in prior studies 
may have resulted from delays in specimen collection. 
This study was designed to eliminate delays in specimen 
collection. The study’s null hypotheses are as follows: 1 )  
TNF levels are not increased in response to trauma, and 
2 )  the time elapsed from injury to sampling does not affect 
the probability of detecting TNF. 
I METHODS 
Study Design: A prospective cross-sectional study was 
performed to associate TNF and IL levels with major 
trauma and interval from injury to specimen collection. 
This study was approved by the institutional review board 
of the University of Michigan Medical Center, and the 
medical control board of Washtenaw and Livingston 
Counties. 
Setting and Population: The study was performed at a 
unicersity hospital ED (Level- 1 trauma center) from May 
1993 to May 1994. The facility manages about 35,000 ED 
visits and 1,100 major trauma cases annually. Specimens 
for analysis were obtained from uninjured healthy vol- 
unteers (“controls”) who also were employees at the in- 
stitution and from major blunt trauma patients (“pa- 
tients”). 
Inclusion criteria for the patients were: adults (age 
2 1 8  years) with class I or I1 trauma as defined by the 
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institutional criteria listed below and specimen drawn <4 
hours from the injury. 
Class I trauma is defined as: Any patient with multi- 
system injury and unstable vital signs, defined as: 
Altered or fluctuating level of consciousness 
Respiratory distress necessitating invasive airway 
Documented hypotension 
Ongoing fluid requirement to maintain blood pres- 
management 
sure 
Class II  trauma is defined as: Any patient with a mech- 
anism suggestive of, or documented, multisystem injury, 
and stable vital signs. defined as the absence of the above 
features, or a stable patient with 2 1  open fracture. 
Patients were excluded from the study if they were 
<18 years of age, in  cardiopulmonary arrest at the scene, 
or >4 hours from injury, or if the blood sample was im- 
properly collected. Patients with penetrating injury, burns, 
inhalational injury, or electric shock were excluded. All 
patients were followed until hospital discharge or death. 
Experimental Protocol: A 5-mL specimen of blood 
was drawn from the controls and the patients. The patients 
had specimens obtained at the scene of the incident, in  
transport to the trauma center, or upon arrival at the 
trauma center. Investigators were notified through the 
medical center’s Trauma Notification System of all in- 
bound severely injured patients. After confirming that the 
patient met study criteria, the investigator on call came to 
the ED to collect specimens obtained in the out-of-hos- 
pita1 setting or in the ED. Specimens were placed into a 
sterile syringe containing 25 p-L of heparin (Elkins-Sinn, 
Inc., Cherry Hill, NJ). Pre-hospital specimens, upon arri- 
val to the ED, were transferred into a 5-mL sterile Ep- 
pendorff tube (Baxter Scientific, Romulus, MI). 
All plasma samples were assayed for TNF, IL-6, and 
IL-8 levels. The specimens were logged in, given a study 
number, and centrifuged immediately at 4,200 rpm for 5 
minutes at 4°C. The plasma was transferred to a sterile 5 -  
mL polypropylene test tube and stored at -70°C until 
assayed for cytokine activity (see below for details). 
Data for each patient were collected after hospital dis- 
charge. Clinical data collected included the time interval 
from injury to specimen collection (AT), the injury se- 
verity scale (ISS) score, and patient demographics. If pa- 
tients were unable to report the time of injury, the injury 
was presumed to have occurred 5 minutes prior to the 9- 
1-1 call for motor vehicle crashes in populated areas and 
witnessed industrial injuries. The time of specimen col- 
lection was obtained either by the on-call investigator’s 
direct observation or by the time documented on the emer- 
gency medical services run sheet or nursing trauma flow 
~ ~~~ ~ ~~ ~ ~~ ~~ 
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sheet. The ISS score was calculated using the 1985 Ab- 
breviated Injury Scale (AIS 85).6 
The WEHI (from the Walter and Eliza- 
beth Hall Institute of Melbourne. Australia) 164 subclone 
13 cell line was used to assess TNF concentration. Plasma 
samples were serially diluted in 96-well plates using a 
multichannel pipette. Dilutions were made in RPMI (Rus- 
well Park Memorial Institute) 1640 wells (Gibco Labo- 
ratories, Grand Island, NY) containing 1% fetal bovine 
serum (FBS) and 1 mmol L-glutamine in a final volume 
of 100 FL. A standard curve of serially-diluted human 
recombinant TNF also was included in each assay. WHEI 
cells were suspended at a concentration of 5 X lo5 cells/ 
mL in RPMI 1640 containing 10% FBS, 30 pg/mL gen- 
tamycin, I mmol L-glutamine, and 0.5 pg/mL Actino- 
mycin D (Calbiochem, Ldolla, CA); 100 p L  was added 
to each sample-containing well. The plates were incubated 
at 37°C in a humidified atmosphere containing S% C 0 2  
for 18-20 hours. MTT-Tetrazolium (20 FL of a 5 mg/mL 
solution, Sigma Laboratory, St. Louis, MO) was added to 
each well, and the plates were allowed to incubate for an 
additional 3 hours. Finally, 150 KL of fluid was aspirated 
from each well using a Bio-Tek plate washer (Bio-Tek 
Instruments, Inc., Winooski, VT), and 100 pL  of 0.04 N 
HCl/isopropanol was added to dissolve the dark blue Te- 
trazolium crystals. The plates were protected from light 
and allowed to stand overnight at room temperature. Ab- 
sorbance was read at 550 nm on a Bio-Tek ELISA reader 
(Bio-Tek Instruments, Inc.), and TNF concentrations were 
calculated based on the recombinant TNF standard.’ 
The B-9 cell line was used to assess IL- 
6 concentrations. Similar to the TNF bioassay, samples 
were serially diluted in 96-weJI plates using Iscove’s Mod- 
ified Dulbecco’s Medium (IMDM, Gibco Laboratories) 
containing 5% FBS, 1 mmol L-glutamine, 100 U/mL pen- 
icillin, and 100 Fg/mL streptomycin. A standard of seri- 
ally-diluted human recombinant IL-6 was run in  each as- 
say. The cultured B-9 cells were washed twice and 
resuspended at a concentration of 5 X lo4 cells/mL in the 
above media supplemented with 100 Fmol 2-mercapto- 
ethanol. Then 100 FL of the cell suspension was added 
to each sample well. The plates were incubated at 37°C 
in a humidified atmosphere containing 5% C 0 2  for ap- 
proximately 72 hours. The plates were then processed as 
described above for the TNF assay, except that they were 
incubated with 3-(4,5-dimethyIthiazol-2-y1)-2,5 diphenyl 
tetrazolium for 6 hours. IL-6 concentrations were calcu- 
lated based on the recombinant IL-6 standard.’ 
The ELISA for IL-8 was developed as 
reported by DeForge and Remick.8 Briefly, a rabbit poly- 
clonal antibody to recombinant mononuclear cell-derived 
(73 amino acid form) human IL-8 was raised, and the IgG 
was isolated from the antisera using a protein A-agarose 




muno Plate Maxisorb, Neptune, NJ) were coated with 50 
pL/well of anti-IL-8 diluted to 1 p,g/mL and incubated 
overnight at 4°C. The plates were washed 3 times using 
phosphate-buffered saline (PBS) containing 0.05% v/v 
polysorbinate 20 (Tween-20), blocking solution [PBS con- 
taining 2% bovine serum albumin (BSA)] was added, and 
the plates were incubated for 1 to 2 hours at 37°C. An IL- 
8 standard curve was prepared using rIL-8, and the sam- 
ples and standards were added to the plates and incubated 
for 1 hour at 37°C. The plates were then washed, bioti- 
nylated rabbit anti-human IL-8 antibody was added, and 
the plates were incubated at 37°C for 30 min. Avidin- 
horseradish peroxidase (Dako, Carpenteria, CA) was di- 
luted to 1:5,000 and added. The plates were again incu- 
bated for 30 min at 37°C. T h e  plates were washed, and 
substrate solution was added [0.67 mg/mL orthophenyl- 
enediamine dichloride (Dako, Santa Barbara, CA), 
0.0125% Hz02 in 0.25 mmol citrate phosphate buffer, pH 
5.01. Color development proceeded for 4 to 5 min at room 
temperature before being stopped by the addition of 50 
pL  3 mol H,SO,. The absorbance was then measured at 
490 nm on an ELISA reader (Biotek, Inc.), and the con- 
centration of IL-8 was calculated based on the standard 
curve of rIL-8. The lower limit of sensitivity for the assay 
was 45 p g / d . ’  
Data Analysis: Characteristics of the patients vs  the 
controls and between the patients subgroups were com- 
pared using the unpaired t-test for interval variables (data 
expressed as mean -t SD) and xz for categorical variables. 
The patients’ cytokine data were grouped by hourly AT 
intervals for comparison of mean levels of TNF, IL-6, and 
IL-8 using multivariate analysis of variance (MANOVA). 
The patients’ specimens also were empirically subdi- 
vided at the observed median AT into “early” and “late” 
specimen collections. The mean cytokine levels for the 
early and late specimens were compared with the mean 
levels for the controls. As there are no established normal 
ranges for these cytokines, values >2.5 SD above the 
mean level for the controls were considered elevated. The 
level of significance was p < 0.05 throughout; all statis- 
tical tests were 2-sided. 
I RESULTS 
A total of 86 patient specimens were studied over a 1- 
year period. After sample collection, 16 specimens were 
subsequently excluded due to contamination (n  = 7),  col- 
lection >4 hours past injury (n = 6), or patient age < I 8  
years (n  = 3). Thus, 70 patients’ specimens were analyzed. 
The mean age and ISS score for the patients were 37 ? 
2 years and 19 i 2, respectively. The mean AT was 92.8 
2 49.2 min (range 10-210 min, median 82 min). As has 
been found previously, there was no correlation between 
severity of injury, trauma class (class I or II), age, or gen- 
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I TABLE 1 Percentage of Subjects with Measurable Cytokine groups using the median AT demonstrated that the late 
patients had significantly lower TNF values (Table 2 ) .  lxvels  and Mean ( 2  SD) Levels for Controls vs Patients . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . .  
C:ytokine* Con~rols Patients p-value 
TNF% measurable 96% 93% NS 
L 6 %  measurable 0% 63% <0.001 
IL-8% measurable 10% 46% <0.05 
TNF (pg/mL) 125 2 149 628 -C 877 <0.05 
IL-6 (pg/niL) 0 2 0  215 2 679 <o.oo I 
IL-8 (pg/mL) 2 ? 7  201 3- 657 <o.o 1 
*TNF = tumor necrosis factor: IL = interleukin 
der of patients and presence of measurable cytokine lev- 
els. Since the controls were healthy volunteers employed 
at the medical center, no demographic data were kept for 
comparison with the patients. 
There was detectable TNF activity in 96% of the con- 
trols and in 93% of the patients. In both groups, TNF was 
detected more frequently than IL-6 or IL-8. The mean 
levels of TNF, IL-6, and IL-8 were all increased i n  the 
patients compared with the controls' mean levels ( p  < 
0.05). The frequencies of detection of TNF were not sig- 
nificantly different, but the mean level of TNF was sig- 
nificantly higher in the patients vs the control group (Table 
1 ). 
When the data were grouped by hour following injury 
(ATj,  mean TNF levels declined over time (Fig. 1; p = 
NS). Although these differences did not obtain statistical 
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. . . . . . . . . . . . . .  . .  . . . . . . . . . . . . . . . . . .  I DISCUSSION 
It is clear from our data that TNF, IL-6 and IL-8 activity 
is detectable in the immediate posttraumatic period. Mean 
levels of all 3 cytokines were higher in the patients than 
in the controls. Absolute TNF levels (756 vs 530 pg/mL; 
p < 0.05) and the proportion of abnormally elevated levels 
of TNF (51% vs 30%; p < 0.07) were higher in the early 
vs late patient groups. This finding is consistent with TNF 
levels declining with longer intervals from injury until 
measurement. Hence, our data are consistent with the the- 
ory that TNF is an active early cytokine in trauma. 
Our results are consistent with the described inflam- 
matory cascade in the sepsis rn~de l . ' . ~ .~  Injection of TNF 
initiates the same pathophysiologic response as does in- 
jection of gram-negative endotoxin lipopolysaccharides 
(LPSS).~.~ Further, pretreatment with anti-TNF antibodies 
is protective from the inflammatory response to injection 
of both TNF and LPS.''." That injury and sepsis would 
use the same mechanism to create the same end response 
is not unexpected; teleologically it makes more sense than 
the presence of 2 different inflammatory mechanisms. Our 
results also are consistent with previous reports of admit- 
ted patients with major trauma, which report n o  direct 
correlation between the magnitude of the injury (ISS), 
age, or gender and injury-associated cytokine  level^.'^-'^ 
Trauma patients who survive their initial injury and 
2 3 
Time from Injury (hours) 
-t 
1 4 
I FIGURE 1. Bar graph showing the decline in tumor necrosis factor (TNF) levels vs time from over 1,600 pg/rnL in the first hour grouping to 
just over 500 pg/mL in the fourth hour grouping (left vertical axis). The filled squares indicate the number of specimens included in each hourly 
grouping (right verticnl axis). 
~ 
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I TABLE 2 Proportion of Patients with Abnormally Elevated Cy- 
tokine Levels (i.e.. >2.5 Times the Mean Value for Controls) and 
Absolute hlean (I-SD) Values for Early vs Late Subgroups of Pa- 
tients, Using the Median Interval from Injury until Presentation as 
the Cutoff Point 
. . . . . . . . . . . . . . . . . . . . . . . . . . . 
Cytokine* Early (<82 min) Late (>82 niin) p-value 
TNF% elevated 19/37 (51%) 10/33 (30%) NS 
IL-6% elevated 23/37 (62%) 21/33 (61%) NS 
IL-8% elevated 15/37 (47%) 14/33 (42%) NS 
TNF (pg/mL) 756 i 1.208 530 i 860 <0.05 
IL-6 (pg/mL) 201 t 977 205 Z 631 NS 
IL-X ( p d m L )  287 5 906 135 5 644 <0.05 
~ ~ ~ _ _ _ _  ~~~ 
*TNF = tumor necrosis factor: IL = interleukin. 
resuscitation phase face delayed complications associated 
with the inflammatory response, thus resulting in signifi- 
cant morbidity and mortality. ARDS alone carries at best 
a 40% mortality While emergency physicians 
(EPs) are generally not managing these complications, 
they may perform an important protective role for their 
patients by modulating the inflammatory response in  pa- 
tients with diagnoses known to carry a risk for delayed 
complications. The setting of major trauma is one in 
which the EP is generally aware of the interval from insult 
until presentation. Given a brief interval from injury until  
medical evaluation, EPs may be able to intervene in the 
ED or potentially in the out-of-hospital setting, using 
agents to block the inflammatory response to trauma. 
I LIMITATIONS AND FUTURE 
QUESTIONS 
This report represents one of the largest series of early 
cytokine levels reported to date for major trauma patients. 
However, by attempting to collect as many specimens as 
close as possible to the point of injury, our AT is skewed 
toward the first hour after injury. This selection bias, while 
helpful for demonstrating that TNF is elevated shortly af- 
ter injury, may have limited our ability to demonstrate the 
reduction in TNF following acute injury. Subsequent stud- 
ies with serial measurements of cytokines following injury 
would be valuable for delineating the effects of time and 
other confounders on these mediators of the inflammatory 
response. Other potential confounders such as patient 
body mass, degree of hypotension, and preexisting illness 
also should be evaluated for their effect on cytokine ac- 
tivity as a function of time. 
Another problem we experienced was the exclusion of 
15 specimens for various reasons. Seven consecutive 
specimens were lost to contamination, which was not rec- 
ognized until the time of specimen assay. This phenom- 
enon is due to the nature of the bioassay. Until the clone 
is incubated with the plasma, contamination is not evident. 
Bacterial contamination ruins the utility of that specimen. 
The other specimens were assayed but their results were 
dropped from data analysis because after review of patient 
charts, the subjects did not meet study entry criteria. Over- 
all, about 18% of the specimens had to be excluded. 
The precise sequence and  duration of cytokine activity, 
direct precipitating causes and  associated effects, have yet 
to be described in humans. While we have demonstrated 
T N F  activity in the response to trauma, serial cytokine 
measurements from individual patients will be needed to 
define normal and pathologic cytokine responses to 
trauma. Given that elevated T N F  activity appears early 
and presumably for a short duration, monitoring of cyto- 
kine levels and the physiologic response to these agents 
must begin during the initial patient resuscitation. 
I CONCLUSION 
While there is baseline T N F  activity in healthy individu- 
als, T N F  activity increases significantly in response to 
trauma. Following major trauma, there also is a significant 
increase in “downstream cytokines.” IL-6 and IL-8. 
These cytokines may increase after T N F  levels peak. Pre- 
vious investigators’ inability to detect this early cytokine 
activity is probably due to delayed specimen collection. 
Further investigation into the  early phase of cytokine re- 
sponse to trauma should begin in the earliest phase of 
care. 
The authors acknowledge the assistance of Ms. Cindy Thoinpwn, Ms. 
Nancy Collins, and Ms. Jennifer F o g a y s .  
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Further Thoughts from the Reviewers 
I The  authors provide important preliminary data related t o  
cytokine levels in  injured patients; however, their data analysis 
likely understates the time dependency of these markers. Given 
the reported large SDs about the mean hourly cytokine levels, 
the authors’ assumption of data distribution normality must be 
called into question. Logarithmic transformation of their data 
may have yielded a more normal data distribution and demon- 
strated a time dependency when the transformed data were an-  
alyzed using a repeated-measures ANOVA. Alternatively, a non- 
parametric analysis (e.g., Friedman 2-way ANOVA by ranks) 
may have provided a more accurate analysis. Future studies in 
this area should pay close attention t o  the distribution of the raw 
data and base the analytical approach accordingly. 
